How a Foundation Built Its Own Drug Program for an Ultra-Rare Disease

Schaaf-Yang syndrome is an ultra-rare neurodevelopmental disorder that is closely related to but distinct from Prader-Willi syndrome. It typically presents from birth with poor muscle tone, feeding and breathing difficulties, and later evolves into a broad spectrum of more severe developmental delay, intellectual disability, autism, endocrine dysfunction, and disruptive sleep patterns. The Foundation for Prader-Willi Research’s GeneSYS initiative is leveraging antisense oligonucleotide technology to knock down the toxic truncated protein underlying Schaaf-Yang, orchestrating collaborations with academic scientists, contract research organizations, and patient families to move from cell and animal models toward first-in-human studies. We spoke to Theresa Strong, director of research programs for the Foundation for Prader-Willi Research, about the challenges of delivering therapy to the hypothalamus, navigating ultra-rare drug economics, and how patient-led organizations can drive sophisticated translational programs for conditions that affect only a few hundred people worldwide.

You can listen to How a Foundation Built Its Own Drug Program for an Ultra-Rare Disease online on Radio and Podcast. Open the player on this page to stream the available audio.

How a Foundation Built Its Own Drug Program for an Ultra-Rare Disease is an episode from RARECast by RARECast.

This episode is 00:35:50 long.

This episode was published on Mar 26, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from RARECast when more episodes are available from the podcast feed.